Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $6.00

Seres Therapeutics (NASDAQ:MCRB) had its price target reduced by stock analysts at Chardan Capital from $8.00 to $6.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock.

Separately, Oppenheimer dropped their price target on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 6th.

Seres Therapeutics Stock Performance

Seres Therapeutics stock opened at $0.75 on Wednesday. The stock’s 50 day simple moving average is $0.83 and its two-hundred day simple moving average is $1.06. The stock has a market cap of $113.17 million, a price-to-earnings ratio of -0.83 and a beta of 2.16. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $6.26.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.08. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.50 million. On average, analysts predict that Seres Therapeutics will post -1.15 earnings per share for the current year.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently made changes to their positions in MCRB. Mirae Asset Global Investments Co. Ltd. bought a new position in Seres Therapeutics in the 1st quarter valued at approximately $39,000. Pennant Investors LP bought a new position in Seres Therapeutics in the 4th quarter valued at approximately $409,000. Tower Research Capital LLC TRC lifted its position in Seres Therapeutics by 668.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 33,135 shares in the last quarter. Handelsbanken Fonder AB lifted its position in Seres Therapeutics by 10.0% in the 4th quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock valued at $1,540,000 after acquiring an additional 100,000 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Seres Therapeutics in the 4th quarter valued at approximately $73,000. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.